Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.33 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.31 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24229270 | 0.79 | SLC40A1 (0.36) | — | |
| SCHEMBL22815779 | 0.76 | ENPP3 (0.45) | SMPD3 | |
| SCHEMBL2885548 | 0.76 | NCF1 (0.39) | NCF1NR4A2SOS2CYP17A1CYP1A2 | |
| SCHEMBL22187775 | 0.75 | PI4KA (0.43) | CYP1A2 | |
| SCHEMBL23619423 | 0.73 | NCF1 (0.41) | NCF1NR4A2SOS2CYP17A1CYP1A2 | |
| SCHEMBL13482934 | 0.73 | NCF1 (0.37) | NCF1NR4A2SOS2CYP17A1CYP1A2 | |
| SCHEMBL12146924 | 0.72 | NCF1 (0.39) | NCF1NR4A2SOS2CYP17A1CYP1A2 | |
| SCHEMBL23346696 | 0.72 | KDM4E (0.41) | NCF1NR4A2 | |
| SCHEMBL23898962 | 0.71 | YTHDC1 (0.42) | CYP1A2 | |
| SCHEMBL22071859 | 0.71 | DYRK1A (0.37) | NCF1NR4A2SOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | NCF1 414/4885NR4A2 739/4885SOS2 2030/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.